Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACAD vs CISS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: ACAD 3 – 3 CISS Matrix Metrics: ACAD 7 – 3 CISS

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). ACAD carries a Unified Composite Score of 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin).

  • Growth vs. Quality Trade-Off: ACAD earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. CISS 33.6/100 SELL) and 0.15β · 90% Vol risk profile, whereas CISS leads top-line expansion (+249.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACAD vs CISS
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
TTM Revenue $1.20B
Forward P/E 15.8x
Beta / 30D Vol 0.15β · 90% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $19.31 · SMA50: $20.80
CISS NASDAQ
C3is Inc. Common Stock
Deep Sea Foreign Transportation Of Freight
$1.23
+4.24% 1D
Market Cap $991,199
TTM Revenue $36.2B
Forward P/E N/M
Beta / 30D Vol 11.91β · 1054% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 5.0 Fund 29.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $1.05 · SMA50: $0.95

6-Pillar Scorecard Institutional Category Breakdown (ACAD 3 – 3 CISS)

Columns: Metric · ACAD · CISS
1. Valuation Multiples ACAD
Forward P/E 15.8x N/M
Trailing P/E 8.3x N/M
PEG Ratio N/M N/M
EV / Revenue 2.3x N/M
2. Growth & Scale CISS
Revenue Growth (YoY) +22.8% +249.0%
Earnings Growth (YoY) -26.2% +193.3%
TTM Revenue (USD) $1.20B $36.2B
Market Cap $3.0B $991,199
3. Profitability & Quality CISS
Gross Margin 63.9% 68.1%
Operating Margin 10.2% 24.6%
Net Profit Margin 30.1% 27.4%
Return on Equity (ROE) 31.4% 17.1%
4. Balance Sheet & Cash Flow CISS
Cash Generation (TTM) $181M $13.4B EBITDA
Cash Flow Margin 15.0% 36.9% EBITDA Mgn
Net Cash / Leverage $251M Net Cash $384.31 Book/Sh · 17.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACAD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 41.7% (6th %ile) N/A (N/A)
Put/Call OI Skew 71.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity 53.7% of Rev ($646M) 43.5% of Rev ($15.8B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Marine Shipping Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACAD (7) vs CISS (3)
Institutional Metric ACAD CISS Criterion Row Edge
Market Capitalization
Scale
$3.0B $991,199 Larger Scale ACAD
Trailing P/E Ratio
Valuation
8.3x N/M Lower Multiple ACAD
Forward P/E Ratio
Valuation
15.8x N/M Lower Multiple ACAD
Revenue Growth (YoY)
Growth
+22.8% +249.0% Higher Growth CISS
Operating Margin (TTM)
Profitability
10.2% 24.6% Higher Margin CISS
Net Profit Margin
Profitability
30.1% 27.4% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
31.4% 17.1% Higher ROE ACAD
52-Week Range Position
Momentum
8% ($16–$31) 20% ($0–$6) Stronger Trend CISS
Beta / 30D Volatility
Risk Regime
0.15β · 90% Vol 11.91β · 1054% Vol Lower Realized Risk ACAD
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 33.6 / 100 (SELL) Higher Composite ACAD
Trailing 12M Revenue (USD)
Operating Scale
$1.20B $36.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.9% 68.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$181M ($251M Net Cash) $13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CISS +150.99 pp
ACAD: -15.76% · CISS: +135.23%
3M Horizon ACAD +10.58 pp
ACAD: -42.29% · CISS: -52.87%
6M Horizon ACAD +28.97 pp
ACAD: -18.91% · CISS: -47.88%
1Y Horizon CISS +0.48 pp
ACAD: -25.93% · CISS: -25.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACAD Revenue CISS Revenue ACAD Op. Margin CISS Op. Margin Margin Leader
FY2018 $220M N/A -110.6% N/A ACAD
FY2019 $340M N/A -72.7% N/A ACAD
FY2020 $440M N/A -64.9% N/A ACAD
FY2021 $480M N/A -35.2% N/A ACAD
FY2022 $520M N/A -43.2% N/A ACAD
FY2023 $730M $30M -10.1% 36.3% CISS
FY2024 $960M $40M 24.1% 23.8% ACAD
FY2025 $1.07B $30M 9.8% 3.9% ACAD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACAD BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 41.7%
IV Percentile 6th %ile
Put/Call OI Skew 71.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CISS BREAKDOWN
64d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $18.67 · IV 48.0%

ACAD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,867)

Compare $1,867 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 48.0% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $17 / $16 Bull Put Spread

Sell 3x $17P · Buy 3x $16P · 32d

Net Entry $75 Credit
Max Credit / Yield +$75 (+33.3% RoM)
Max Risk / Buffer -10.3% Cushion ($225 Mgn)
5d Edge & Liquidity 76% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $20 / $17 Bear Put Spread

Buy 1x $20P · Sell 1x $17P · 32d

Net Entry $85 Debit
T+5d @ -5% Drop +$54 (+64%)
Max Risk / Buffer $85 Capped
5d Edge & Liquidity 1.4x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published
CISS Moat Profile Scale & Operating Efficiency Moat
Marine Shipping Operator
Competes within the Marine Shipping value chain with $991,199 market capitalization and 24.6% operating margin.
OpEx & R&D Reinvestment 43.5% of Rev ($15.8B)
90D Engineering Disclosures 0 Published

Investor FAQ ACAD vs CISS Key Questions & Quantitative Answers

As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). ACAD carries a Unified Composite Score of 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin). Growth vs. Quality Trade-Off: ACAD earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. CISS 33.6/100 SELL) and 0.15β · 90% Vol risk profile, whereas CISS leads top-line expansion (+249.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CISS leads the Growth & Scale pillar: ACAD posts +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin), compared with CISS at +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACAD cumulative revenue shifted +386.4% while CISS shifted +0.0%. In operating R&D and SG&A reinvestment, ACAD deploys 53.7% of Rev ($646M) (0 90-day corporate R&D disclosures) versus 43.5% of Rev ($15.8B) (0 disclosures) for CISS.

ACAD screens cheaper on headline valuation multiples. ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin), whereas CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACAD (31.4% ROE) versus CISS (17.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk). By comparison, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.